Two peptides can act on the same cell in two opposite ways without canceling each other out
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are contraindicated during breastfeeding per UK Summary of Product Characteristics No weight loss injection currently has regulatory approval for use whilst breastfeeding in the UK Transfer into breast milk and effects on nursing infants remain unknown due to absence of human studies Appetite suppression from these medications may compromise maternal nutrition needed for adequate milk production Safe alternatives include gradual dietary modification, regular physical activity, and NHS weight management programmes Women should defer weight loss medications until breastfeeding is completed and seek GP advice for postpartum weight concerns Table of Contents Weight Loss Injections and Breastfeeding: Key Safety Considerations Types of Weight Loss Injections and Their Use During Lactation Potential Risks to Breastfed Infants Alternative Approaches to Postpartum Weight Management When to Seek Medical Advice About Weight Loss While Breastfeeding Scientific References Frequently Asked Questions Weight Loss Injections and Breastfeeding: Key Safety Considerations Weight loss injections, particularly GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), have become increasingly popular for weight management
vitamin B12 150 mcg
INJECTION Dosage Guidelines Other Other, To be used under medical supervision, typically started on the 5th day of the menstrual cycle
Standard cognitive support protocols use much lower doses, typically 100 to 200 mcg administered intranasally once or twice daily
Vitamin B12 is an essential water-soluble vitamin that plays a key role in metabolism, energy production, red blood cell formation, and nervous system health
